infectious diseases

News

GSK wins FDA green light for chronic hep B treatment Hibsago

GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.

News

Aicuris acquisition delivers new drug for Asahi Kasei

Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the deal.

News

ViiV's Cabenuva enhances control of unsuppressed HIV

ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.

News

New York declares measles outbreak a "disaster emergency"

The governor of New York has said rising cases of measles constitute a statewide disaster emergency, as cases in neighbouring Pennsylvania pass 1,000.

News

Vaxcyte's pneumococcal jab exceeds expectations

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.

News

Mirum puts Hepcludex in its sights with hep D readout

Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.

GSK wins FDA green light for chronic hep B treatment Hibsago

Aicuris acquisition delivers new drug for Asahi Kasei

ViiV's Cabenuva enhances control of unsuppressed HIV

New York declares measles outbreak a "disaster emergency"

Vaxcyte's pneumococcal jab exceeds expectations

Mirum puts Hepcludex in its sights with hep D readout

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

infectious diseases

Editor's Picks